TR201005726T2 - Docetaksel içeren stabilize tekli-sıvı farmasötik kompozisyon. - Google Patents

Docetaksel içeren stabilize tekli-sıvı farmasötik kompozisyon.

Info

Publication number
TR201005726T2
TR201005726T2 TR2010/05726T TR201005726T TR201005726T2 TR 201005726 T2 TR201005726 T2 TR 201005726T2 TR 2010/05726 T TR2010/05726 T TR 2010/05726T TR 201005726 T TR201005726 T TR 201005726T TR 201005726 T2 TR201005726 T2 TR 201005726T2
Authority
TR
Turkey
Prior art keywords
composition
pharmaceutical composition
liquid pharmaceutical
docetaxel
composition containing
Prior art date
Application number
TR2010/05726T
Other languages
English (en)
Inventor
Cha Bong-Jin
Yoo Moo-Hi
Jang Sun-Woo
Kim Jeong-Hoon
Won Dong-Han
Original Assignee
Dong-A Pharm. Co. , Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201005726(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong-A Pharm. Co. , Ltd. filed Critical Dong-A Pharm. Co. , Ltd.
Publication of TR201005726T2 publication Critical patent/TR201005726T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bu buluş docetaksel içeren enjeksiyon amaçlı tekli-sıvı bir farmasötik kompozisyonla ilgilidir Bu kompozisyon (A) docetaksel ve bunun farmasötik olarak kabul edilebilir tuzlarını, (B) polisorbat, polioksietilen glikol ester ve polioksietilen limityağı türevlerinden oluşan gruptan seçilen bir yüzey aktif madde, (C) enjekte edilebilir bir solüsyonda 100 ila 800 mg/ml arasında bir konsantrasyonda susuz etanol içeren bir solvent, ve (D) sıvı kompozisyonun pH derecesinin 5 ya da daha az olacak şekilde ayarlanması için uygun olan bir miktarda bir pH ayarlayıcı içermektedir. Bu kompozisyon, kompozisyonun enjekte edilebilir preparatlar için kullanılması durumunda bir ara seyreltik solüsyonun kullanımı olmadan bile bir perfüzyon sıvısında doğrudan seyreltilebilir çünkü bu kompozisyon tekli bir sıvı fazdadır
TR2010/05726T 2008-02-29 2009-02-26 Docetaksel içeren stabilize tekli-sıvı farmasötik kompozisyon. TR201005726T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080019179A KR101053780B1 (ko) 2008-02-29 2008-02-29 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
PCT/KR2009/000911 WO2009107983A2 (ko) 2008-02-29 2009-02-26 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물

Publications (1)

Publication Number Publication Date
TR201005726T2 true TR201005726T2 (tr) 2011-10-21

Family

ID=41016586

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/05726T TR201005726T2 (tr) 2008-02-29 2009-02-26 Docetaksel içeren stabilize tekli-sıvı farmasötik kompozisyon.

Country Status (14)

Country Link
US (1) US20100267818A1 (tr)
JP (1) JP5552438B2 (tr)
KR (1) KR101053780B1 (tr)
CN (1) CN101959501B (tr)
AU (1) AU2009217927B2 (tr)
BR (1) BRPI0908859A2 (tr)
CA (1) CA2714942C (tr)
MX (1) MX2010009031A (tr)
MY (1) MY152013A (tr)
NZ (1) NZ587578A (tr)
RU (1) RU2478370C2 (tr)
TR (1) TR201005726T2 (tr)
WO (1) WO2009107983A2 (tr)
ZA (1) ZA201004462B (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5824511B2 (ja) * 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
WO2012161520A2 (ko) * 2011-05-23 2012-11-29 에스케이케미칼 주식회사 도세탁셀을 함유하는 액상 주사용 조성물
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
JP5847942B2 (ja) * 2012-07-19 2016-01-27 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN103040739B (zh) * 2013-01-11 2014-07-23 罗诚 一种含有多西他赛化合物的药物组合物
JP6124633B2 (ja) * 2013-03-18 2017-05-10 ダイト株式会社 安定なドセタキセル注射剤
KR20140147336A (ko) * 2013-06-19 2014-12-30 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
CN103432109B (zh) * 2013-09-01 2015-09-23 吴静 紫杉醇的药物组合物
CN104546694A (zh) * 2013-10-15 2015-04-29 悦康药业集团有限公司 一种多西他赛注射液及其制备方法
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN105395540A (zh) * 2015-12-01 2016-03-16 海南通用康力制药有限公司 一种多西他赛注射液及其制备方法
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
KR102401546B1 (ko) * 2020-03-25 2022-05-27 주식회사 보령 탁산, 이의 약학적으로 허용되는 염, 또는 그의 수화물을 함유하는 안정성이 향상된 신규 약제학적 제형
US20230364172A1 (en) * 2022-05-14 2023-11-16 Syncotrance, LLC Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
HK1052655A1 (zh) * 2000-01-05 2003-09-26 纽里姆药品(1991)有限公司 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
JP2005225818A (ja) * 2004-02-13 2005-08-25 Otsuka Pharmaceut Factory Inc パクリタキセル又はドセタキセルの医薬組成物
MX2007010394A (es) * 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
EP2138164A1 (en) * 2005-06-17 2009-12-30 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
KR100995390B1 (ko) * 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
EP2012749A2 (en) * 2006-05-03 2009-01-14 I.Q.A., A.S. Pharmaceutical composition containing a taxane derivative, destined for the preparation of an infusion solution, method of preparation thereof and use thereof
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
JP2010530872A (ja) * 2007-06-22 2010-09-16 サイドース・エルエルシー Ｔｗｅｅｎ８０を含まないドセタキセル可溶化製剤

Also Published As

Publication number Publication date
KR20090093581A (ko) 2009-09-02
ZA201004462B (en) 2011-04-28
JP2011513299A (ja) 2011-04-28
WO2009107983A3 (ko) 2009-12-03
AU2009217927B2 (en) 2012-06-07
CN101959501A (zh) 2011-01-26
MX2010009031A (es) 2010-09-10
US20100267818A1 (en) 2010-10-21
CA2714942A1 (en) 2009-09-03
CN101959501B (zh) 2012-08-29
RU2010139958A (ru) 2012-04-10
AU2009217927A1 (en) 2009-09-03
RU2478370C2 (ru) 2013-04-10
KR101053780B1 (ko) 2011-08-02
NZ587578A (en) 2012-08-31
JP5552438B2 (ja) 2014-07-16
WO2009107983A2 (ko) 2009-09-03
CA2714942C (en) 2014-06-17
MY152013A (en) 2014-08-15
BRPI0908859A2 (pt) 2017-06-06

Similar Documents

Publication Publication Date Title
MY152013A (en) Stabilized single-liquid pharmaceutical composition containing docetaxel
Chao et al. Cystathionine-β-synthase inhibition for colon cancer: enhancement of the efficacy of aminooxyacetic acid via the prodrug approach
Fraga-Silva et al. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension
Graziani et al. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis
Wang et al. Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5
ES2753639T3 (es) Acidos tetrahidrocannabinol-11-oicos para su uso en el tratamiento de enfermedades fibróticas
ATE464062T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
AR054215A1 (es) Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
Ma et al. Polyethylene glycol 400 (PEG400) affects the systemic exposure of oral drugs based on multiple mechanisms: taking berberine as an example
AR079836A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
JP2015531374A5 (tr)
Li et al. Research progress on GPX4 targeted compounds
EP3213769A1 (en) Transdermal-absorption-promoter and transdermal-absorption-promoting supplement
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
MX2021007393A (es) Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
Kunimatsu et al. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats
Ramachandran et al. Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors
Takasawa et al. The powerful potential of amino acid menthyl esters for anti‐inflammatory and anti‐obesity therapies
NO20070832L (no) Farmasoytiske preparat av piperazinderivater.
WO2008077772A3 (en) Combination of a retinoid and a platinum anticancer agent
Rautio et al. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor
Zhang et al. Vericiguat as a novel PPARα ligand alleviates pressure-overload-induced heart failure
Mrestani et al. Influence of absorption enhancers on the pharmacokinetic properties of non-oral β-lactam-cefpirom using the rabbit (chinchilla) in vivo model
DE602005009915D1 (de) Zweiphasige Zusammensetzung enthaltend ein Natriumsalz eines Esters des Dimethiconcopolyols mit Sulfobernsteinsäure, und ihre Verwendung in der Kosmetik